HUP0303264A3 - Carbamate compounds for use in preventing and treating neurodegenerative disorders - Google Patents

Carbamate compounds for use in preventing and treating neurodegenerative disorders

Info

Publication number
HUP0303264A3
HUP0303264A3 HU0303264A HUP0303264A HUP0303264A3 HU P0303264 A3 HUP0303264 A3 HU P0303264A3 HU 0303264 A HU0303264 A HU 0303264A HU P0303264 A HUP0303264 A HU P0303264A HU P0303264 A3 HUP0303264 A3 HU P0303264A3
Authority
HU
Hungary
Prior art keywords
preventing
neurodegenerative disorders
treating neurodegenerative
carbamate compounds
carbamate
Prior art date
Application number
HU0303264A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of HUP0303264A2 publication Critical patent/HUP0303264A2/hu
Publication of HUP0303264A3 publication Critical patent/HUP0303264A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU0303264A 2001-02-27 2002-02-21 Carbamate compounds for use in preventing and treating neurodegenerative disorders HUP0303264A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27168201P 2001-02-27 2001-02-27
PCT/US2002/005541 WO2002067925A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating neurodegenerative disorders
US10/081,764 US20020165273A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating neurodegenerative disorders

Publications (2)

Publication Number Publication Date
HUP0303264A2 HUP0303264A2 (hu) 2004-01-28
HUP0303264A3 true HUP0303264A3 (en) 2012-07-30

Family

ID=26765943

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303264A HUP0303264A3 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing and treating neurodegenerative disorders

Country Status (26)

Country Link
US (3) US20020165273A1 (enExample)
EP (1) EP1383489B1 (enExample)
JP (1) JP4276840B2 (enExample)
KR (1) KR100910928B1 (enExample)
CN (1) CN1235579C (enExample)
AR (1) AR035756A1 (enExample)
AT (1) ATE361745T1 (enExample)
BR (1) BR0207645A (enExample)
CA (1) CA2439295C (enExample)
CY (1) CY1106753T1 (enExample)
CZ (1) CZ301203B6 (enExample)
DE (1) DE60220043T2 (enExample)
DK (1) DK1383489T3 (enExample)
ES (1) ES2284845T3 (enExample)
HU (1) HUP0303264A3 (enExample)
IL (2) IL157591A0 (enExample)
MX (1) MXPA03007718A (enExample)
MY (1) MY138156A (enExample)
NO (1) NO20033798L (enExample)
NZ (1) NZ527990A (enExample)
PL (1) PL364680A1 (enExample)
PT (1) PT1383489E (enExample)
RS (1) RS51055B (enExample)
RU (1) RU2300373C2 (enExample)
TW (1) TWI312679B (enExample)
WO (1) WO2002067925A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033092A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
PT1809273E (pt) * 2004-09-16 2010-05-10 Janssen Pharmaceutica Nv Utililização de 2-fenil-1,2-etanodiol-(di)carbamatos para tratamento de epileptogénese
BRPI0516112A (pt) * 2004-10-15 2008-08-26 Janssen Pharmaceutica Nv métodos para neuroproteção
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
EP1928451B1 (en) * 2005-07-26 2011-12-28 SK Biopharmaceuticals Co., LTD Methods for treating substance-related disorders
US7632963B2 (en) * 2006-10-06 2009-12-15 Janssen Pharmaceutica Nv Crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
CN101568362A (zh) * 2006-10-30 2009-10-28 詹森药业有限公司 治疗抑郁症的方法
JP2010508354A (ja) * 2006-10-31 2010-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 広汎性発達障害の処置
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
WO2012002773A2 (en) * 2010-07-02 2012-01-05 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
WO2013036678A1 (en) * 2011-09-07 2013-03-14 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
RU2632659C2 (ru) 2011-12-27 2017-10-09 Байо-Фарм Солюшнс Ко., Лтд. Фенилкарбаматные соединения для применения в предупреждении или лечении эпилепсии
JP6062077B2 (ja) * 2013-03-12 2017-01-18 バイオ−ファーム ソリューションズ カンパニー リミテッド 小児てんかん及びてんかん関連症侯群の予防又は治療用フェニルカルバメート化合物｛ｐｈｅｎｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｐｅｄｉａｔｒｉｃｅｐｉｌｅｓｙａｎｄｅｐｉｌｅｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅｓ｝
WO2014142547A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for neuroprotection comprising the same
CN109071424B (zh) 2016-02-29 2022-01-14 生物药品解决方案有限公司 氨基磺酸酯衍生物化合物、其制备方法及用途
ES3035674T3 (en) 2016-12-14 2025-09-08 Sk Biopharmaceuticals Co Ltd Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease
IL281559B2 (en) * 2018-09-21 2025-06-01 Sk Biopharmaceuticals Co Ltd (r)-1-phenyl-2-tetrazolyl ethyl carbamate derivatives and formulations comprising same for use in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
WO2022045824A1 (en) 2020-08-31 2022-03-03 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease
US11896593B2 (en) 2020-09-10 2024-02-13 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3278380A (en) * 1962-02-06 1966-10-11 Armour Pharma Methods of calming employing diphenyl hydroxy carbamate compounds
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
CN1109880A (zh) * 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
RS50676B (sr) * 2001-02-27 2010-06-30 Ortho-Mcneil Pharmaceutical Inc. Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
DK1401424T3 (da) * 2001-02-27 2007-02-26 Ortho Mcneil Pharm Inc Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af psykotiske forstyrrelser
HUP0303243A3 (en) * 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing and treating bipolar disorder

Also Published As

Publication number Publication date
DE60220043T2 (de) 2008-01-10
CZ301203B6 (cs) 2009-12-09
JP2004523555A (ja) 2004-08-05
KR100910928B1 (ko) 2009-08-06
DE60220043D1 (de) 2007-06-21
CN1235579C (zh) 2006-01-11
NO20033798L (no) 2003-09-26
IL157591A (en) 2009-12-24
ES2284845T3 (es) 2007-11-16
BR0207645A (pt) 2004-12-28
JP4276840B2 (ja) 2009-06-10
ATE361745T1 (de) 2007-06-15
AR035756A1 (es) 2004-07-07
HUP0303264A2 (hu) 2004-01-28
US20040171679A1 (en) 2004-09-02
RU2300373C2 (ru) 2007-06-10
RU2003128982A (ru) 2005-03-10
HK1065486A1 (en) 2005-02-25
CN1503667A (zh) 2004-06-09
PL364680A1 (en) 2004-12-13
CZ20032313A3 (cs) 2004-08-18
US20020165273A1 (en) 2002-11-07
CY1106753T1 (el) 2012-05-23
WO2002067925A1 (en) 2002-09-06
HK1060516A1 (en) 2004-08-13
NZ527990A (en) 2006-01-27
NO20033798D0 (no) 2003-08-26
CA2439295C (en) 2010-05-25
TWI312679B (en) 2009-08-01
US20090005442A1 (en) 2009-01-01
MY138156A (en) 2009-04-30
RS67403A (sr) 2006-12-15
PT1383489E (pt) 2007-06-21
IL157591A0 (en) 2004-03-28
EP1383489B1 (en) 2007-05-09
EP1383489A1 (en) 2004-01-28
CA2439295A1 (en) 2002-09-06
MXPA03007718A (es) 2004-11-12
DK1383489T3 (da) 2007-08-06
RS51055B (sr) 2010-10-31
KR20030076714A (ko) 2003-09-26

Similar Documents

Publication Publication Date Title
IL157591A0 (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
HUP0303344A3 (en) Carbamate compounds for use in preventing and treating movement disorders
IL208191A0 (en) Compositions and methods for treating rage-associated disorders
IL233205B (en) Substances for the treatment or prevention of pre-eclampsia
IL160388A0 (en) Topical compositions and methods for treating pain
PT2311466E (pt) Compostos antimicrobianos e métodos para a sua utilização
HUP0400069A3 (en) Pharmaceutical combinations and their use in preventing and treating the thrombosis
GB2425617B (en) Device for preventing and treating myopia
HUS1300035I1 (hu) Dihidroimidazolonok alkalmazása epilepszia kezelésére kutyákban
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
HUP0303261A3 (en) Carbamate compounds for use in preventing or treating bipolar disorder
HUP0303243A3 (en) Carbamate compounds for use in preventing and treating bipolar disorder
IL157593A0 (en) Carbamate compounds for use in the treatment of pain
HUP0303342A3 (en) Carbamate compounds for use in preventing and treating psychotic disorders
HUP0401913A3 (en) Medicine for preventing and treating bromhidrosis
HUP0301553A3 (en) Pharmaceutical compositions and their use for treating neurological disorders
GB0119025D0 (en) Compounds and their therapeutic use
AU2003278935A8 (en) Method and composition for treating neurodegenerative disorders
EP1425020A4 (en) METHOD AND COMPOSITIONS FOR TREATING APOPTOSIS-RELATED DISEASES
AU2003297259A8 (en) Methods and compositions for treating neurological disorders
ZA200307473B (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders.
IL159846A0 (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
ZA200307477B (en) Carbamate compounds for use in preventing or treating movement disorders.
ZA200604723B (en) Agents for preventing and/or treating higher brain dysfunctions
GB0112236D0 (en) Compounds and their therapeutic use

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees